Immuneering (IMRX) EPS (Weighted Average and Diluted) (2020 - 2023)
Historic EPS (Weighted Average and Diluted) for Immuneering (IMRX) over the last 4 years, with Q4 2023 value amounting to -$0.55.
- Immuneering's EPS (Weighted Average and Diluted) fell 942.81% to -$0.55 in Q4 2023 from the same period last year, while for Sep 2024 it was -$0.52, marking a year-over-year increase of 7108.12%. This contributed to the annual value of -$1.93 for FY2023, which is 97.7% down from last year.
- As of Q4 2023, Immuneering's EPS (Weighted Average and Diluted) stood at -$0.55, which was down 942.81% from -$0.45 recorded in Q3 2023.
- In the past 5 years, Immuneering's EPS (Weighted Average and Diluted) ranged from a high of -$0.05 in Q4 2021 and a low of -$1.61 during Q2 2021
- In the last 4 years, Immuneering's EPS (Weighted Average and Diluted) had a median value of -$0.5 in 2022 and averaged -$0.67.
- Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first surged by 9576.27% in 2021, then plummeted by 90000.0% in 2022.
- Immuneering's EPS (Weighted Average and Diluted) (Quarter) stood at -$1.18 in 2020, then soared by 95.76% to -$0.05 in 2021, then crashed by 900.0% to -$0.5 in 2022, then fell by 9.43% to -$0.55 in 2023.
- Its EPS (Weighted Average and Diluted) stands at -$0.55 for Q4 2023, versus -$0.45 for Q3 2023 and -$0.43 for Q2 2023.